Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
tanibirumab（一种针对血管内皮生长因子受体 2 的全人源单克隆抗体）治疗难治性实体瘤患者的 I 期试验和药代动力学研究
期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-017-0463-y
Lee, Su Jin; Lee, Seon Young; Lee, Weon Sup; Yoo, Jin San; Sun, Jong-Mu; Lee, Jeeyun; Park, Se Hoon; Park, Joon Oh; Ahn, Myung-Ju; Lim, Ho Yeong; Kang, Won Ki; Park, Young Suk
